Evaluation of Effectiveness and Safety of Resolute Onyx in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Phase of Trial: Phase IV
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Zotarolimus (Primary)
- Indications Arterial occlusive disorders; Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- 25 Jan 2017 Planned number of patients changed from 1000 to 4000.
- 25 Jan 2017 Planned End Date changed from 1 Oct 2022 to 31 Oct 2022.
- 25 Jan 2017 Planned primary completion date changed from 1 Oct 2018 to 31 Oct 2018.